TEL AVIV - Peregrine Ventures, an Israeli venture capital fund focused on medical technology, said on Monday it closed its fourth fund, raising $115 million. Peregrine said its partners include institutional and private equity investors from Israel, the United States, Europe and Australia. Peregrine 4 will invest in early and late stage rounds of medical technology startups. Peregrine now has over $200 million under management, and an equal amount available for co-investment, follow-on, and late stage investments in its portfolio companies from Peregrine 1, 2, and 3. The firm has completed 10 exits totalling more than $2 billion in cumulative value. “There is a huge demand, and opportunity, in medical technologies in Israel and foreign investors recognise this,” Peregrine managing partner Eyal Lifschitz said.
